HOT-HMV study shows increase in admission-free survival with non-invasive ventilation devices Lumis, Stellar and Astral in chronic obstructive pulmonary disease- ResMed

ResMed has announced positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study regarding the benefits of home non-invasive ventilation (NIV) devices Lumis, Stellar and Astral for chronic obstructive pulmonary disease. Lumis, Stellar and Astral are ventilator systems that can be used by COPD patients at different stages of their disease.

The HOT-HMV study shows that the addition of home NIV to home oxygen therapy improves admission-free survival in hypercapnic COPD patients (those with high levels of carbon dioxide in the blood) following a life-threatening exacerbation of COPD requiring acute NIV. This includes an increase in patients� median (hospital) admission-free survival from 1.4 months in the group receiving HOT only, to 4.3 months in the group receiving HOT plus home NIV. Previous studies also confirm that home NIV can successfully reduce mortality and exacerbation-related hospitalisations and improve patients� quality of life.

See: "Home Mechanical Ventilation (HMV) Following Life Threatening Exacerbations of COPD: A UK Multicentre Randomised Controlled Trial." Murphy P. and Hart N. Abstract presented at the European Respiratory Society annual congress 2016, London.